Posts

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

on

GoodRx Expands Access to Eli Lilly's New Oral GLP-1 Foundayo and Zepbound KwikPen with Self-Pay Pricing at Over 70,000 Pharmacies

on

China Approves Pfizer's GLP-1 Obesity Drug Xianweiying Shortly After Licensing Deal with Sciwind

on

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

on

Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

China Approves Lilly and Innovent's Mazdutide, Marking New Era for GLP-1 Obesity Drugs

on

BrightGene's Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

on

BrightGene's BGM0504 Outperforms Novo Nordisk's Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

on